{"id":"insulin-human-hr1799","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a biosynthetic human insulin produced via recombinant DNA technology. It mimics endogenous insulin by binding to insulin receptors on muscle, fat, and liver cells, facilitating glucose transport into cells and promoting glycogen synthesis while inhibiting gluconeogenesis. HR1799 is Sanofi's formulation of human insulin for parenteral administration in diabetes management.","oneSentence":"Insulin human (HR1799) is a recombinant human insulin that binds to insulin receptors on cells to promote glucose uptake and regulate blood glucose levels.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:49:15.755Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT01194882","phase":"PHASE3","title":"Benefit/Risk Evaluation of Insuman Implantable Versus Insuplant Using Medtronic MiniMed Implantable Pump System in Patients With Type 1 Diabetes","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-11-16","conditions":"Diabetes Mellitus, Type 1","enrollment":479},{"nctId":"NCT01630369","phase":"PHASE4","title":"Efficacy and Safety of Insuman Basal/Comb/Rapid in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-02","conditions":"Type 2 Diabetes Mellitus","enrollment":552},{"nctId":"NCT01353469","phase":"PHASE3","title":"Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin® 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin Therapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-05","conditions":"Type 2 Diabetes Mellitus","enrollment":485},{"nctId":"NCT00523393","phase":"PHASE4","title":"Prospective Influence of Bedtime Insulin Glargine on Mobilization and Function of Endothelial Progenitor Cells","status":"UNKNOWN","sponsor":"Heidelberg University","startDate":"2007-08","conditions":"Type 2 Diabetes","enrollment":75}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Insuman Basal / Insuman Comb / Insuman Rapid"],"phase":"marketed","status":"active","brandName":"insulin human (HR1799)","genericName":"insulin human (HR1799)","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Insulin human (HR1799) is a recombinant human insulin that binds to insulin receptors on cells to promote glucose uptake and regulate blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}